In this Issue:
EGFR TKIs may improve DFS in EGFR-mutant NSCLC
Afatinib vs gefitinib in treatmentnaïve EGFR-mutant NSCLC
VATS vs open surgery in early-stage NSCLC
Nivolumab ± ipilimumab active in recurrent SCLC
Dabrafenib promising in BRAFV 600E-mutant NSCLC
Dabrafenib + trametinib in BRAFV 600E-mutant NSCLC
Malignancies in new solid nodules with low-dose CT screening
The MAGE-A3 immunotherapeutic disappoints
First-line therapy of advanced NSCLC: nivolumab alone
. . . or in combination with platinum doublet chemotherapy
Please login below to download this issue (PDF)